GlobeNewswire Inc. · Apr 15, 2024
Orgenesis Provides Year End Business Update
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera
OR
OTC · ORGS
Orgenesis Inc.
Healthcare · Biotechnology
$0.35
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 3:28 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.15M
- P/E ratio
- 48.51
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 100
- Avg. volume
- 1.12K
Price performance
ORGS price history
1M range · 0 trading sessions · Daily adjusted prices
ORGS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ORGS news
The latest Smart Investors Daily articles mentioning ORGS.
Stock researchCompany · Overview
ORGS research
Overview
Company profile and research snapshot.
Company profile
ORGENESIS INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 14, 2023 | Benchmark | Speculative Buy | — |
| Mar 22, 2023 | Benchmark | Buy | — |
| Sep 26, 2019 | Benchmark | Speculative Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 10, 2024
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services. The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
GlobeNewswire Inc. · Mar 4, 2024
Orgenesis Inc. Announces $2.3 Million Private Placement
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. The warrants are exercisable immediately and expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.
GlobeNewswire Inc. · Feb 29, 2024
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM). The consortium members include: Orgenesis Services Belgium, Université catholique de Louvain (UCLouvain) / TRusted AI Labs (TRAIL) and DNAlytics. Advanced Therapy Medicinal Products (ATMPs) are among the most innovative and promising biomedicines designed to address unmet medical needs, including cell, gene, exosome and phage therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
